<DOC>
	<DOCNO>NCT02558387</DOCNO>
	<brief_summary>Recently , sorafenib target VEGFR PDGFR demonstrate 13-16 % response rate patient recurrent/metastatic salivary gland cancer , suggest VEGFR PDGFR might important role salivary gland cancer . Accordingly , several trial various anti-angiogenic molecular target agent dasatinib , dovitinib , sunitinib salivary gland cancer ongoing . Nintedanib ( BIBF1120 ) potent small molecule triple receptor tyrosine kinase inhibitor ( PDGFR/ FGFR1-2 VEGFR1-3 ) . VEGFR-2 consider crucial receptor involve initiation formation well maintenance tumor vasculature . In vitro , target receptor inhibit nintedanib low nanomolar concentration . In vivo nude mouse model , nintedanib show good anti-tumor efficacy dose 50-100mg/kg , leading substantial delay tumor growth even complete tumor stasis xenograft broad range differ human tumor . Based background , study , investigator would like conduct phase II study Nintedanib ( BIBF 1120 ) patient recurrent metastatic salivary gland cancer head neck evaluate efficacy safety .</brief_summary>
	<brief_title>Trial BIBF1120 ( Nintedanib ) Patients With Recurrent Metastatic Salivary Gland Cancer Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Histologically proven salivary gland cancer head neck ( According WHO classification , mucoepidermoid cancer , adenoid cystic carcinoma , adenocarcinoma/salivary duct cancer eligible ) Recurrent metastatic salivary gland cancer head neck patient fail one line systemic chemotherapy age â‰¥ 18 year At least one measurable tumor lesion accord RECIST 1.1 ECOG performance status 02 Adequate hematologic function ( absolute neutrophil count &gt; 1,500/m/ , platelet &gt; 100,000/ml , haemoglobin &gt; 9.0 g/dl ) , hepatic function ( alanine transaminase/aspartate transaminase &lt; 5 x ULN , total bilirubin &lt; 1.5 x ULN ) , renal function ( creatinine clearance &gt; 45 ml/min ) Written informed consent Uncontrolled systemic illness DM , CHF , unstable angina , hypertension , history myocardial infarction 12 month prior start treatment , arrhythmia Hemorrhagic thromboembolic event past 6 month Major injury 10 day prior start study Patients postobstructive pneumonia uncontrolled serious infection Pregnant nursing woman Uncontrolled symptomatic brain metastasis Prior history malignancy within 5 year study entry except adequately treat basal cell squamous cell skin cancer situ cervical cancer , well treat thyroid cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>